PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18

The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99

Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50

Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol (2008) 2.39

Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood (2012) 1.95

SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev (2009) 1.78

PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood (2009) 1.74

Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72

The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol (2009) 1.71

BCL11B is required for positive selection and survival of double-positive thymocytes. J Exp Med (2007) 1.59

PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One (2014) 1.46

BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol (2006) 1.45

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44

Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A (2013) 1.42

Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol (2005) 1.40

The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity (2014) 1.40

Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev (2009) 1.39

Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 1.39

HTLV-1 bZIP Factor Enhances T-cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog (2017) 1.38

Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc Natl Acad Sci U S A (2011) 1.34

Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol (2006) 1.30

Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol (2011) 1.29

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28

Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A (2007) 1.28

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity (2016) 1.27

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med (2011) 1.27

Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood (2012) 1.25

The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol (2011) 1.22

PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection. Immunology (2010) 1.21

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 1.21

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep (2015) 1.18

HIV-induced changes in T cell signaling pathways. J Immunol (2008) 1.16

TLR-mediated induction of negative regulatory ligands on dendritic cells. J Mol Med (Berl) (2008) 1.09

Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J Immunol (2012) 1.08

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol (2014) 1.07

New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci (2015) 1.02

The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol (2014) 1.01

PD-1 coinhibitory signals: the link between pathogenesis and protection. Semin Immunol (2013) 1.01

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun (2016) 0.98

New antibody approaches to lymphoma therapy. J Hematol Oncol (2014) 0.97

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. Int J Mol Sci (2016) 0.97

Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology (2013) 0.97

Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol (2016) 0.96

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity (2016) 0.96

Influenza infection results in local expansion of memory CD8(+) T cells with antigen non-specific phenotype and function. Clin Exp Immunol (2014) 0.94

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget (2015) 0.93

PD-1 regulates neural damage in oligodendroglia-induced inflammation. PLoS One (2009) 0.92

Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One (2012) 0.92

Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A (2015) 0.91

Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J (2014) 0.89

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res (2016) 0.89

Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annu Rev Virol (2015) 0.89

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci (2016) 0.88

Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res (2015) 0.88

Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. PLoS One (2014) 0.87

PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res (2016) 0.86

Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta (2015) 0.86

Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathog (2011) 0.85

PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. Immunology (2010) 0.85

PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol (2010) 0.84

MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. Immunol Endocr Metab Agents Med Chem (2012) 0.84

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. Immunity (2016) 0.84

PD-1 as an immune modulatory receptor. Cancer J (2014) 0.84

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer (2015) 0.83

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest (2016) 0.83

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res (2015) 0.82

Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J Autoimmun (2014) 0.82

The immunological synapse: the gateway to the HIV reservoir. Immunol Rev (2013) 0.82

Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol (2015) 0.81

TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS One (2015) 0.81

CD8+ memory T cells appear exhausted within hours of acute virus infection. J Immunol (2013) 0.81

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget (2016) 0.81

PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology (2015) 0.80

CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. J Immunol (2015) 0.80

PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. Oncoimmunology (2015) 0.80

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol (2016) 0.80

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med (2016) 0.80

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders. Front Cell Neurosci (2014) 0.79

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell (2016) 0.78

PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB. Cancer Res (2015) 0.78

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther (2016) 0.78

Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunol Rev (2017) 0.78

Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. Cell Mol Immunol (2016) 0.78

Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol (2016) 0.78

The Etiologic Role of Infectious Antigens in Sarcoidosis Pathogenesis. Clin Chest Med (2015) 0.77

SHP-1: the next checkpoint target for cancer immunotherapy? Biochem Soc Trans (2016) 0.77

Radiation-induced immune responses: mechanisms and therapeutic perspectives. Blood Res (2016) 0.76

ssTherapeutic Effect of Human Ghrelin and Growth Hormone: Attenuation of Immunosuppression in Septic Aged Rats. Biochim Biophys Acta (2017) 0.76

Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap (2015) 0.75

Exhaustion-associated regulatory regions in CD8(+) tumor-infiltrating T cells. Proc Natl Acad Sci U S A (2017) 0.75

Liver sinusoidal endothelial cell-mediated CD8 T cell priming depends on co-inhibitory signal integration over time. PLoS One (2014) 0.75

Destabilizing the autoinhibitory conformation of Zap70 induces up-regulation of inhibitory receptors and T cell unresponsiveness. J Exp Med (2017) 0.75

Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? Front Immunol (2015) 0.75

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation. Front Immunol (2017) 0.75

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (2003) 6.07

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78

IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity (2002) 3.17

The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem (2002) 3.01

Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem (2007) 2.06

Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03

The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol (2008) 1.82

Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol (2003) 1.68

Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood (2005) 1.61

Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol (2008) 1.59

Comparative proteomic characterization of articular cartilage tissue from normal donors and patients with osteoarthritis. Arthritis Rheum (2007) 1.48

Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). J Biol Chem (2004) 1.38

Binding and localization of recombinant lubricin to articular cartilage surfaces. J Orthop Res (2007) 1.34

Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol (2006) 1.34

Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis. J Biol Chem (2003) 1.29

IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res (2009) 1.27

Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol Cell Proteomics (2005) 1.22

Proteomic characterization of the dynamic KSR-2 interactome, a signaling scaffold complex in MAPK pathway. Biochim Biophys Acta (2009) 1.00

Synthesis and PKCtheta inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles. Bioorg Med Chem Lett (2008) 0.99

Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1. J Leukoc Biol (2006) 0.98

Analysis of the human sperm proteome. Ann N Y Acad Sci (2005) 0.96

A fluorescent assay suitable for inhibitor screening and vanin tissue quantification. Anal Biochem (2009) 0.93

Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-α production in a receptor for advanced glycation end product-dependent manner. J Immunol (2010) 0.92

2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta. Bioorg Med Chem Lett (2008) 0.92

Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem (2012) 0.90

The plant pathogenesis related protein GLIPR-2 is highly expressed in fibrotic kidney and promotes epithelial to mesenchymal transition in vitro. Matrix Biol (2006) 0.89

Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol (2005) 0.88

Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors. J Med Chem (2008) 0.87

Identification and characterization of acidic mammalian chitinase inhibitors. J Med Chem (2010) 0.87

Proteomic identification of endothelial proteins isolated in situ from atherosclerotic aorta via systemic perfusion. J Proteome Res (2007) 0.86

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther (2007) 0.86

Altered regulation of aquaporin gene expression in allergen and IL-13-induced mouse models of asthma. Cytokine (2009) 0.85

The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease. Cell Immunol (2011) 0.84

NAK is recruited to the TNFR1 complex in a TNFalpha-dependent manner and mediates the production of RANTES: identification of endogenous TNFR-interacting proteins by a proteomic approach. J Biol Chem (2004) 0.83

Characterization of protein kinase C theta activation loop autophosphorylation and the kinase domain catalytic mechanism. Biochemistry (2005) 0.83

Natural killer cells from protein kinase C theta-/- mice stimulated with interleukin-12 are deficient in production of interferon-gamma. J Leukoc Biol (2008) 0.81

First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett (2009) 0.80

Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases. Biochem J (2009) 0.79

Evolutionary and biochemical differences between human and monkey acidic mammalian chitinases. Gene (2009) 0.78

Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions. J Biol Chem (2012) 0.78

C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II. Bioorg Med Chem Lett (2009) 0.78

Engineered protein inhibitors of proteases. Curr Opin Drug Discov Devel (2006) 0.78

Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin. Biochemistry (2005) 0.78

Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles. Bioorg Med Chem Lett (2009) 0.77

ROCK2 associates with lectin-like oxidized LDL receptor-1 and mediates oxidized LDL-induced IL-8 production. Am J Physiol Cell Physiol (2010) 0.77

Second generation 4-(4-methyl-1H-indol-5-ylamino)-2-phenylthieno[2,3-b]pyridine-5-carbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett (2008) 0.77

Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCtheta inhibitors. Bioorg Med Chem Lett (2009) 0.77

Optimization of 5-vinylaryl-3-pyridinecarbonitriles as PKCtheta inhibitors. Bioorg Med Chem Lett (2010) 0.76

Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles. Bioorg Med Chem Lett (2009) 0.76

C-5 Substituted heteroaryl 3-pyridinecarbonitriles as PKCtheta inhibitors: Part I. Bioorg Med Chem Lett (2009) 0.76

Corrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonists. Nat Chem Biol (2015) 0.76

Synthesis of 3-farnesyl salicylic acid, a novel antimicrobial from Piper multiplinervium. Nat Prod Commun (2013) 0.75

Binding characterization of the interleukin-13 signaling complex and development of a ternary time-resolved fluorescence resonance energy transfer assay. Anal Biochem (2008) 0.75